REUTERS - Pfizer Inc is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab Ltd (STAR.NS), for a possible price of $2 billion, Bloomberg reported on Monday.
Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.
A Pfizer spokeswoman said the company does not comment on market rumours or speculation.
Agila makes cancer treatments and antibiotics, Bloomberg said.
Pfizer shares were up 23 cents at $26.75 on the New York Stock Exchange. (Reporting By Caroline Humer; editing by John Wallace)
Trending On Reuters
India's biggest airline, IndiGo, is likely to file the prospectus for a stock market listing that will raise around $400 million later on Tuesday, two banking sources with knowledge of the matter said. Article